Literature DB >> 77321

Multiple sclerosis: demyelination and myelination inhibition of organotypic tissue cultures of the spinal cord by sera of patients with multiple sclerosis and other neurological diseases.

J Ulrich, H Lardi.   

Abstract

Sera from 44 patients with Multiple Sclerosis, of three patients with neurological syndromes compatible with Multiple Sclerosis, of 34 patients suffering from other neurological diseases and of 25 pregnant healthy young women were tested for their demyelinating activity in myelinated tissue cultures. In order to leave the investigators unprejudiced, all sera were coded and intermixed with controls of rabbit EAE serum which had a potent demyelinating capacity. Demyelination was graded (from 0--4), heat lability at 56 degrees C (complement dependency?) was also tested with each serum. Only demyelination of a degree of 2 and more, which was abolished by heating to 56 degrees C, was counted as positive. Six of the 44 sera from MS patients (13.6%), 19 of 37 sera from neurological patients and none of the healthy young women demyelinated. Thus, serum demyelination of tissue cultures seems to be a nonspecific indicator of chronic disease of the nervous system and is of considerable general neurological interest, but does not indicate a demyelinating disease. Myelination inhibition was not observed with any of the human sera tested for it.

Entities:  

Mesh:

Year:  1978        PMID: 77321     DOI: 10.1007/BF00314713

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  A tissue-culture approach to demyelinative disorders.

Authors:  M B BORNSTEIN
Journal:  Natl Cancer Inst Monogr       Date:  1963-03

2.  FUNCTIONAL STUDIES OF CULTURED BRAIN TISSUES AS RELATED TO "DEMYELINATIVE DISORDERS".

Authors:  M B BORNSTEIN; S M CRAIN
Journal:  Science       Date:  1965-05-28       Impact factor: 47.728

3.  [Determination of the gliotoxie and demyelinating properties of serum in organ cultures of brain in experimental allergic encephalomyelitis].

Authors:  L I Ravkina; A G Goriunova
Journal:  Zh Nevropatol Psikhiatr Im S S Korsakova       Date:  1976

4.  The initial structural lesion in serum-induced demyelination in vitro.

Authors:  M B Bornstein; C S Raines
Journal:  Lab Invest       Date:  1976-10       Impact factor: 5.662

5.  Neuroelectric blocking factors in multiple sclerosis and normal human sera.

Authors:  F J Seil; A L Leiman; J M Kelly
Journal:  Arch Neurol       Date:  1976-06

6.  Experimental allergic encephalomyelitis: demyelinating activity of serum and sensitized lymph node cells on cultured nerve tissues.

Authors:  M B Bornstein; H Iwanami
Journal:  J Neuropathol Exp Neurol       Date:  1971-04       Impact factor: 3.685

7.  Lack of correlation between changes in bioelectric functions and myelin in cultured CNS tissues chronically exposed to sera from animals with EAE.

Authors:  M B Bornstein; S M Crain
Journal:  J Neuropathol Exp Neurol       Date:  1971-01       Impact factor: 3.685

8.  Multiple sclerosis: serum factor producing reversible alterations in bioelectric responses.

Authors:  J A Cerf; G Carels
Journal:  Science       Date:  1966-05-20       Impact factor: 47.728

9.  Anti-synaptic antibody in allergic encephalomyelitis. I. Neurophysiological studies, in guinea pigs, on the exposed cerebral cortex and peripheral nerves, following immunological challenges with myelin and synaptosomes.

Authors:  C E Lumsden; L Howard; S R Aparicio
Journal:  Brain Res       Date:  1975-08-08       Impact factor: 3.252

10.  About demyelinating properties of humoral antibodies in experimental allergic encephalomyelitis. In vivo and in vitro studies.

Authors:  K Kristensson
Journal:  Acta Neuropathol       Date:  1976-12-21       Impact factor: 17.088

View more
  3 in total

1.  Degradation of human myelin in vitro by leucocytes from patients with multiple sclerosis.

Authors:  S J Owen; C M Watson; A N Davison
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

2.  Upregulation of glycolytic enzymes, mitochondrial dysfunction and increased cytotoxicity in glial cells treated with Alzheimer's disease plasma.

Authors:  Tharusha Jayasena; Anne Poljak; Nady Braidy; George Smythe; Mark Raftery; Mark Hill; Henry Brodaty; Julian Trollor; Nicole Kochan; Perminder Sachdev
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 3.  Abnormalities of serum and plasma components in patients with multiple sclerosis.

Authors:  H C Ford
Journal:  Clin Biochem       Date:  1985-02       Impact factor: 3.281

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.